FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval. (PubMed, Cancers (Basel)) - Sep 27, 2026 - "All patients had received first-line FOLFOX plus cetuximab or panitumumab, followed by FOLFIRI plus bevacizumab after progression...OFI was associated with PFS in a nonlinear manner, but there was no robust evidence that it modified the relative treatment effect across its continuous range. Exploratory subgroup findings based on a 6-month cutoff require external validation."
Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • BRAF • KRAS
|
|
Deniz Isik; Goncagul Akdag; Hatice Odabas; Nedim Turan; Sedat Yildirim; Sila Oksuz; Tugba Basoglu; Ugur Ozkerim; Yunus Emre Altintas
|